PEG Produkte
(Polyethylene Glycol (PEG))
Kategorien
Anti-PEG antibodies are being used to monitor the pharmacokinetics of PEGylated compounds and ensure their quality control for therapeutic use. This application has become particularly important with the development of nanomedicines, as patients have developed reactions to some nanoparticles without a clear understanding of what causes the reactions. The use of anti-PEG antibodies can help in identifying potential issues with nanomedicines and improving their safety.
PEGylation increases the half-life, reduces immunogenicity, and improves solubility and stability of biological molecules such as proteins or enzymes. PEG molecules can vary in size and shape, allowing for modulation of pharmacological output for different drug therapies. PEGylation has been applied in the clinic for over 25 years and is a well-established method in the field of targeted drug delivery systems. PEGylation has the potential to improve therapeutic outcomes and reduce toxicity of encapsulated and/or conjugated drugs. However, there are potential drawbacks that may inhibit their widespread use in designing site-specific drug delivery systems.
antibodies-online.com steht für hochwertige Forschungsprodukte. Suchen, finden und bestellen Sie Tools mit umfangreichen Validierungsdaten, Bildern, Referenzen. Unser wissenschaftlicher Kundenservice steht Ihnen jederzeit zur Verfügung, wenn Sie Fragen zur Auswahl oder Anwendung unserer Produkte haben.
Empfohlene PEG Antikörper
- (5)
- (3)
- (3)
- (3)
Empfohlene PEG ELISA Kits
- (1)
Neueste Publikationen zu unseren PEG Produkten
: "Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma." in: Oncogenesis, Vol. 8, Issue 3, pp. 18, (2019) (PubMed).: "Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts." in: Respiratory research, Vol. 18, Issue 1, pp. 80, (2018) (PubMed).
: "Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models." in: Oncology reports, Vol. 40, Issue 4, pp. 1994-2004, (2018) (PubMed).
: "Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer." in: Cancer science, Vol. 109, Issue 11, pp. 3471-3482, (2018) (PubMed).
: "Cross-Reactivity of Select PEG-Binding Antibodies to Other Polymers Containing a C-C-O Backbone." in: ACS biomaterials science & engineering, Vol. 3, Issue 8, pp. 1605-1615, (2017) (PubMed).
